Sentinel lymph node biopsy and melanoma: 2010 update : Part II - 24/04/13
, Lilit Garibyan, MD, PhD, Arthur J. Sober, MD
Reprint requests: William G. Stebbins, MD, Massachusetts General Hospital, Department of Dermatology, 55 Fruit St, Bartlett Hall 616, Boston, MA 02114.Abstract |
This article will discuss the evidence for and against the therapeutic efficacy of early removal of potentially affected lymph nodes, morbidity associated with sentinel lymph node biopsy and completion lymphadenectomy, current guidelines regarding patient selection for sentinel lymph node biopsy, and the remaining questions that ongoing clinical trials are attempting to answer. The Sunbelt Melanoma Trial and the Multicenter Selective Lymphadenectomy Trials I and II will be discussed in detail.
Learning objectives |
At the completion of this learning activity, participants should be able to discuss the data regarding early surgical removal of lymph nodes and its effect on the overall survival of melanoma patients, be able to discuss the potential benefits and morbidity associated with complete lymph node dissection, and to summarize the ongoing trials aimed at addressing the question of therapeutic value of early surgical treatment of regional lymph nodes that may contain micrometastases.
Le texte complet de cet article est disponible en PDF.Key words : melanoma, Multicenter Selective Lymphadenectomy Trial, sentinel lymph node biopsy
Abbreviations used : CLND, DFS, ELND, IHC, MR, MSLT, NSN, OS, RT-PCR, SLN, SLNB, TLND, WLE
Plan
| Drs Stebbins and Garibyan contributed equally to this work. |
|
| Funding sources: None. |
|
| Conflicts of interest: The authors, editors, and peer reviewers have no relevant financial relationships. |
Vol 62 - N° 5
P. 737-748 - mai 2010 Retour au numéro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?